Steven Brugger
Chief Executive Officer
BrainChild Bio
Kids-first clinical-stage biotech developing CAR T therapies for CNS tumors
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
BrainChild Bio is a clinical-stage biotechnology company developing CAR T cell therapies for tumors in the central nervous system. It prioritizes pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG), with plans to expand its platform to adult CNS indications such as glioblastoma. The company is based in Seattle and Cambridge and spun out of research at Seattle Children’s.
- Website
- brainchildbio.com
- Stage
- series-a
- Founded
- 2023
- Location
- Seattle, United States
- Added via
- web
- Ownership
- unclaimed